<?xml version="1.0"?>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger</dc:title>
  <dc:creator>Campagne, G.</dc:creator>
  <dc:creator>Garba, A.</dc:creator>
  <dc:creator>Fabre, P.</dc:creator>
  <dc:creator>Schuchat, A.</dc:creator>
  <dc:creator>Ryall, R.</dc:creator>
  <dc:creator>Boulanger, D.</dc:creator>
  <dc:creator>Bybel, M.</dc:creator>
  <dc:creator>Carlone, G.</dc:creator>
  <dc:creator>Briantais, P.</dc:creator>
  <dc:creator>Ivanoff, B.</dc:creator>
  <dc:creator>Xerri, B.</dc:creator>
  <dc:creator>/Chippaux, Jean-Philippe</dc:creator>
  <dc:subject>EPIDEMIE</dc:subject>
  <dc:subject>ENFANT D'AGE PRESCOLAIRE</dc:subject>
  <dc:subject>VACCINATION</dc:subject>
  <dc:subject>DOSE</dc:subject>
  <dc:subject>TOXICITE</dc:subject>
  <dc:subject>IMMUNITE</dc:subject>
  <dc:subject>METHODE D'ANALYSE</dc:subject>
  <dc:subject>TEST ELISA</dc:subject>
  <dc:subject>TEST BIOLOGIQUE</dc:subject>
  <dc:subject>ETUDE EXPERIMENTALE</dc:subject>
  <dc:subject>ETUDE COMPARATIVE</dc:subject>
  <dc:subject>MENINGITE</dc:subject>
  <dc:subject>MEND</dc:subject>
  <dc:subject>MENPS</dc:subject>
  <dc:subject>PRP T</dc:subject>
  <dc:description>Background : High rates of endemic disease and recurrent epidemics of serogroup A and C meningococcal meningitis continue to occur in sub-Saharan Africa. A meningococcal A+ + C polysaccharide diptheria-toxoid-conjugated vaccine may address this issue. Methods : In Niger three doses of a bivalent meningococcal A + C diphtheria-toxoid-conjugated vaccine (MenD), containing 1, 4 or 16 micrometer grams of each polysaccharide per dose, administered at 6, 10 and 14 weeks of age, were compared with Haemophilus influenzae type b-tetanus toxoid-conjugated (PRP-T) vaccine given with the same schedule or with a meningococcal A + C polysacharide vaccine (MenPS) given at 10 and 14 weeks of age. One blood sample was taken at the time of enrollment (6 weeks of age) and another was taken 4 weeks after the primary series. Results : all doses of MenD were well-tolerated. After the primary series a higher proportion of infants had detectable serum bactericidal activity against serogroup A for each dose of MenD (from 94% to 100%) than for MenPS (31%) or H. influenzae type b-tetanus toxoid-conjuugated vaccine (18.9%) ; P is less than or equal to 0.05. Significant differences were also observed for serogroup C MenD 4 micrometer grams or MenD 16 micrometer grams (100%) vs. MenPS (69.7%) or Haemophilus influenzae type b-tetanus toxoid-conjugated vaccine (24.3%) ; P is less than or equal to 0.05. When MenPS vaccine was given to 11-month children, the immune response measured by both enzyme-linked immunosorbent assay and serum bactericidal assay was greater in those previously immunized with MenD than in those immunized with MenPS vaccine. Conclusion : MenD was safe among infants in Niger, and immunization led to significantly greater functional antibody activity than with MenPS. The 4-micrometer gram dose of MedD for both the A and C serogroups has been selected for further studies. (R&#xE9;sum&#xE9; d'auteur)</dc:description>
  <dc:date>2000</dc:date>
  <dc:type>text</dc:type>
  <dc:identifier>https://www.documentation.ird.fr/hor/fdi:010026109</dc:identifier>
  <dc:identifier>fdi:010026109</dc:identifier>
  <dc:identifier>Campagne G., Garba A., Fabre P., Schuchat A., Ryall R., Boulanger D., Bybel M., Carlone G., Briantais P., Ivanoff B., Xerri B., Chippaux Jean-Philippe. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. 2000, 19,  144-150</dc:identifier>
  <dc:language>EN</dc:language>
  <dc:coverage>NIGER</dc:coverage>
  <dc:coverage>NIAMEY</dc:coverage>
</oai_dc:dc>
